Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study

Melissa Piliang,Charles Lynde, Brett King,Paradi Mirmirani,Rodney Sinclair,Robert Wolk, Samuel Zwillich,Helen Tran,Fan Zhang,Liza Takiya

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY（2023）

引用 0|浏览6

暂无评分

摘要

Background: This post hoc analysis of the ALLEGRO phase 2b/3 study (NCT03732807) assessed the sustained response to ritlecitinib, an oral JAK3/TEC inhibitor, over 48 weeks in patients with alopecia areata (AA).

查看译文

关键词

alopecia areata,eyelash hair regrowth,ritlecitinib,eyebrow,post-hoc

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要